AID  Vol.7 No.2 , June 2017
Comparative Study of the Mutant Prevention Concentrations of Sulfamethoxazole-Trimethoprim Alone and in Combination with Levofloxacin against Stenotrophomonas maltophilia
Abstract: Objectives: To determine the mutant prevention concentration (MPC) of sulfamethoxazole-trimethoprim (SXT) alone and in combination with levofloxacin (LVX) against Stenotrophomonas maltophilia (S. maltophilia) and to determine if the combination may decrease the emergence of resistant mutants. Methods: The MPC with 20 S. maltophilia strains which were both susceptible to SXT and LVX were determined by inhibiting visible growth among 1010 CFU on four agar plates after 72 hours incubation at 37°C. Results: All except two strains (18/20) showed a mutant prevention concentration ≥ 152/8 μg/mL for SXT and the range of the mutant prevention concentration for the SXT in combination with LVX is 9.5/0.5~608/32 μg/mL, which demonstrates at least 2 fold reduction except one strain. There was a significant difference (P < 0.01) between SXT alone and in combination with LVX on the mutant prevention concentration and mutant prevention concentration/minimum inhibitory concentration values. Conclusions: The MPC/MIC values were narrowed for SXT by combining with LVX against the S maltophilia. The combination may decrease the enrichment of mutant bacterial populations. Much study is needed to verify whether the using of drug combinations may restrict or even block the selection of S. maltophilia mutants.

Cite this paper: Xu, X. , Chen, X. , Sun, N. , Yin, J. and Li, J. (2017) Comparative Study of the Mutant Prevention Concentrations of Sulfamethoxazole-Trimethoprim Alone and in Combination with Levofloxacin against Stenotrophomonas maltophilia. Advances in Infectious Diseases, 7, 45-53. doi: 10.4236/aid.2017.72006.

[1]   Rattanaumpawan, P., Ussavasodhi, P., Kiratisin, P. and Aswapokee, N. (2013) Epidemiology of Bacteremia Caused by Uncommon Non-Fermentative Gram-Negative Bacteria. BMC Infectious Diseases, 13, 167-175.

[2]   Brooke, J.S. (2012) Stenotrophomonas maltophilia: An Emerging Global Opportunistic Pathogen. Clinical Microbiology Reviews, 25, 2-41.

[3]   Sanchez, M.B., Hernandez, A. and Martinez, J.L. (2009) Stenotrophomonas maltophilia Drug Resistance. Future Microbiology, 4, 655-660.

[4]   Looney, W.J., Narita, M. and Muhlemann, K. (2009) Stenotrophomonas maltophilia: An Emerging Opportunist Human Pathogen. The Lancet Infectious Diseases, 9, 312-323.

[5]   Laxminarayan, R., Duse, A. and Wattal, C. (2013) Antibiotic Resistance—The Need for Global Solutions. The Lancet Infectious Diseases, 13, 1057-1098.

[6]   Drlica, K. (2003) The Mutant Selection Window and Antimicrobial Resistance. Journal of Antimicrobial Chemotherapy, 52, 11-17.

[7]   Venkidusamy, K. and Megharaj, M. (2016) Identification of Electrode Respiring, Hydrocarbonoclastic Bacterial Strain Stenotrophomonas maltophilia MK2 Highlights the Untapped Potential for Environmental Bioremediation. Frontiers in Microbiology, 9, 1965-1970.

[8]   Ni, W., Song, X. and Cui, J. (2014) Testing the Mutant Selection Window Hypothesis with Escherichia coli Exposed to Levofloxacin in a Rabbit Tissue Cage Infection Model. European Journal of Clinical Microbiology & Infectious Diseases, 33, 385-389.

[9]   Rhee, J.Y., Song, J.H. and Ko, K.S. (2016) Current Situation of Antimicrobial Resistance and Genetic Differences in Stenotrophomonas maltophilia Complex Isolates by Multilocus Variable Number of Tandem Repeat Analysis. Infection & Chemotherapy, 48, 285-293.

[10]   Morero, N.R., Monti, M.R. and Argarana, C.E. (2011) Effect of Ciprofloxacin Concentration on the Frequency and Nature of Resistant Mutants Selected from Pseudomonas aeruginosa mutS and mutT Hypermutators. Antimicrobial Agents and Chemotherapy, 55, 3668-3676.

[11]   Cai, Y., Yang, J., Kan, Q., et al. (2012) Mutant Prevention Concentration of Colistin Alone and in Combination with Levofloxacin or Tobramycin against Multidrug-Resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 40, 477-478.

[12]   Shimizu, T., Harada, K. and Kataoka, Y. (2013) Mutant Prevention Concentration of Orbifloxacin: Comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of Canine Origin. Acta Veterinaria Scandinavica, 55, 37-41.

[13]   Firsov, A.A., Vostrov, S.N., Lubenko, I.Yu., Portnoy, Y.A. and Zinner, S.H. (2004) Prevention of the Selection of Resistant Staphylococcus aureus by Moxifloxacin plus Doxycycline in an in Vitro Dynamic Model: An Additive Effect of the Combination. International Journal of Antimicrobial Agents, 23, 451-456.

[14]   Liu, L.G., Zhu, Y.L., Hu, L.F., Cheng, J., Ye, Y. and Li, J.B. (2013) Comparative Study of the Mutant Prevention Concentrations of Vancomycin Alone and in Combination with Levofloxacin, Rifampicin and Fosfomycin against Methicillin-Resistant Stapylococcus epidermidis. The Journal of Antibiotics, 66, 709-712.

[15]   Clinical and Laboratory Standard Institute (2013) Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement M100-S22. CLSI, Wayne Pennsylvania, 100-109.

[16]   Blondeau, J., Zhao, X., Hansen, G. and Drlica, K. (2001) Mutant Prevention Concentrations (MPC) of Fluoroquinolones with Clinical Isolates of Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy, 45, 433-438.

[17]   Malinowski, A.M., McClarty, B.M., Robinson, C., et al. (2017) Polysorbate 80 and Polymyxin B Inhibit Stenotrophomonas maltophilia Biofilm. Diagnostic Microbiology and Infectious Disease, 87, 154-156.

[18]   Falagas, M.E., Kastoris, A.C., Vouloumanou, E.K. and Dimopoulos, G. (2009) Community-Acquired Stenotrophomonas maltophilia Infections: A Systematic Review. European Journal of Clinical Microbiology & Infectious Diseases, 28, 719-730.

[19]   Hu, L.F., Gao, L.P., Ye, Y., et al. (2014) Susceptibility of Stenotrophomonas maltophilia Clinical Strains in China to Antimicrobial Combinations. Journal of Chemotherapy, 26, 282-286.

[20]   Zhao, X. and Drlica, K. (2008) A Unified Anti-Mutant Dosing Strategy. Journal of Antimicrobial Chemotherapy, 62, 434-436.

[21]   Zhu, Y.L., Hu, L.F., Mei, Q., et al. (2012) Testing the Mutant Selection Window in Rabbits Infected with Methicillin-Resistant Staphylococcus aureus Exposed to Vancomycin. Journal of Antimicrobial Chemotherapy, 67, 2700-2706.

[22]   Canton, R. and Morosini, M.-I. (2011) Emergence and Spread of Anti Biotic Resistance Following Exposure to Antibiotics. FEMS Microbiology Reviews, 35, 977-991.

[23]   Zhao, X. and Drlica, K. (2001) Restricting the Selection of Antibiotic Resistant Mutants: A General Strategy Derived from Fluoroquinolone Studies. Clinical Infectious Diseases, 33, S147-S156.

[24]   Kucers, A., Scrowe, S., Grayson, M.L., et al. (1997) The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, and Antiviral Drugs. 5th Edition, Butterworth-Heinemann, Boston, MA.

[25]   Zhanel, G.G., Mayer, M., Laing, N. And Adam, H.J. (2006) Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 50, 2228-2230.

[26]   Abdullah, M.R. and Abdulkareem, M.S. (2009) Mutant Prevention Concentration of Levofloxacin Alone and in Combination with Ceftazidime against Levofloxacin and Ceftazidime Sensitive and Resistant Isolates of Pseudomonas aeruginosa. Iraqi Journal of Science, 50, 491-495.